Back to top
more

Ascendis Pharma (ASND)

(Delayed Data from NSDQ)

$134.46 USD

134.46
223,436

-0.85 (-0.63%)

Updated Jun 4, 2024 04:00 PM ET

After-Market: $134.55 +0.09 (0.07%) 6:52 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (87 out of 249)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for ASND

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Ascendis Pharma A/S [ASND]

Reports for Purchase

Showing records 81 - 100 ( 303 total )

Company: Ascendis Pharma A/S

Industry: Medical - Biomedical and Genetics

Record: 81

02/17/2023

Company Report

Pages: 8

Q4/FY22: SKYTROFA Growth Continues; All Eyes on TC-PTH/HP PDUFA in April

Provider: Wedbush Securities Inc.

Analyst: ARGYRIDES A

Price: 12.50

Research Provided by a Third Party

Company: Ascendis Pharma A/S

Industry: Medical - Biomedical and Genetics

Record: 82

02/13/2023

Industry Report

Pages: 4

BEST IDEAS LIST

Provider: Wedbush Securities Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Company: Ascendis Pharma A/S

Industry: Medical - Biomedical and Genetics

Record: 83

01/18/2023

Industry Report

Pages: 4

BEST IDEAS LIST

Provider: Wedbush Securities Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Company: Ascendis Pharma A/S

Industry: Medical - Biomedical and Genetics

Record: 84

01/10/2023

Industry Report

Pages: 4

BEST IDEAS LIST

Provider: Wedbush Securities Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Company: Ascendis Pharma A/S

Industry: Medical - Biomedical and Genetics

Record: 85

01/09/2023

Daily Note

Pages: 9

MORNING CALL

Provider: Wedbush Securities Inc.

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Company: Ascendis Pharma A/S

Industry: Medical - Biomedical and Genetics

Record: 86

01/09/2023

Company Report

Pages: 8

Vision 3x3 Comes Into Focus; Ophthalmology Selected as New Therapeutic Area

Provider: Wedbush Securities Inc.

Analyst: ARGYRIDES A

Price: 12.50

Research Provided by a Third Party

Company: Ascendis Pharma A/S

Industry: Medical - Biomedical and Genetics

Record: 87

01/03/2023

Industry Report

Pages: 41

Biotech vs. The Recession --> We Like The Odds

Provider: Wedbush Securities Inc.

Analyst: CHICO L

Price: 50.00

Research Provided by a Third Party

Company: Ascendis Pharma A/S

Industry: Medical - Biomedical and Genetics

Record: 88

01/03/2023

Industry Report

Pages: 26

2023 Outlook - New Commercial Launches, Clinical Catalysts & M&A Driving Value

Provider: Wedbush Securities Inc.

Analyst: Research Department

Price: 35.00

Research Provided by a Third Party

Company: Ascendis Pharma A/S

Industry: Medical - Biomedical and Genetics

Record: 89

12/23/2022

Industry Report

Pages: 8

The Week Ahead in Life Sciences

Provider: Wedbush Securities Inc.

Analyst: NIERENGARTEN D

Price: 12.50

Research Provided by a Third Party

Company: Ascendis Pharma A/S

Industry: Medical - Biomedical and Genetics

Record: 90

12/21/2022

Industry Report

Pages: 4

BEST IDEAS LIST

Provider: Wedbush Securities Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Company: Ascendis Pharma A/S

Industry: Medical - Biomedical and Genetics

Record: 91

12/12/2022

Industry Report

Pages: 4

BEST IDEAS LIST

Provider: Wedbush Securities Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Company: Ascendis Pharma A/S

Industry: Medical - Biomedical and Genetics

Record: 92

12/05/2022

Company Report

Pages: 7

FDA Allows Expanded Access Program for TC-PTH Ahead of April 30, 2023 PDUFA

Provider: Wedbush Securities Inc.

Analyst: ARGYRIDES A

Price: 12.50

Research Provided by a Third Party

Company: Ascendis Pharma A/S

Industry: Medical - Biomedical and Genetics

Record: 93

11/23/2022

Industry Report

Pages: 4

BEST IDEAS LIST

Provider: Wedbush Securities Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Company: Ascendis Pharma A/S

Industry: Medical - Biomedical and Genetics

Record: 94

11/15/2022

Daily Note

Pages: 8

MORNING CALL

Provider: Wedbush Securities Inc.

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Company: Ascendis Pharma A/S

Industry: Medical - Biomedical and Genetics

Record: 95

11/14/2022

Company Report

Pages: 8

Key Takeaways from Ph2 ACcompliSH Data Follow-Up Call for TC-CNP/ACH

Provider: Wedbush Securities Inc.

Analyst: ARGYRIDES A

Price: 12.50

Research Provided by a Third Party

Company: Ascendis Pharma A/S

Industry: Medical - Biomedical and Genetics

Record: 96

11/14/2022

Company Report

Pages: 12

Positive TC-CNP & Early TC-TLR7/8 Agonist Data Highlight TransCon''s Versatility

Provider: Wedbush Securities Inc.

Analyst: ARGYRIDES A

Price: 12.50

Research Provided by a Third Party

Company: Ascendis Pharma A/S

Industry: Medical - Biomedical and Genetics

Record: 97

11/14/2022

Daily Note

Pages: 9

MORNING CALL

Provider: Wedbush Securities Inc.

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Company: Ascendis Pharma A/S

Industry: Medical - Biomedical and Genetics

Record: 98

11/11/2022

Daily Note

Pages: 14

MORNING CALL

Provider: Wedbush Securities Inc.

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Ascendis Pharma A/S

Industry: Medical - Biomedical and Genetics

Record: 99

11/03/2022

Daily Note

Pages: 14

MORNING CALL

Provider: Wedbush Securities Inc.

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Ascendis Pharma A/S

Industry: Medical - Biomedical and Genetics

Record: 100

11/03/2022

Company Report

Pages: 8

Q3: SKYTROFA Sales Take Off; Multiple Value-Driving Catalysts in Q4

Provider: Wedbush Securities Inc.

Analyst: ARGYRIDES A

Price: 12.50

Research Provided by a Third Party